Edition:
United States

Kaken Pharmaceutical Co Ltd (4521.T)

4521.T on Tokyo Stock Exchange

5,700JPY
18 Aug 2017
Change (% chg)

¥-70 (-1.21%)
Prev Close
¥5,770
Open
¥5,700
Day's High
¥5,720
Day's Low
¥5,660
Volume
84,000
Avg. Vol
161,696
52-wk High
¥6,970
52-wk Low
¥5,410

Latest Key Developments (Source: Significant Developments)

Kaken Pharmaceutical receives marketing approval for Jublia in S.Korea
Wednesday, 17 May 2017 03:07am EDT 

May 17 (Reuters) - Kaken Pharmaceutical Co Ltd <4521.T> ::* Says product Jublia, topical formulation for Onychomycosis, has received marketing approval in South Korea.  Full Article

Acrux says U.S. Patent and Trademark Office institutes IPR proceeding against a U.S. Patent
Monday, 1 May 2017 09:14pm EDT 

May 2 (Reuters) - Acrux Ltd :U.S. Patent and Trademark Office has instituted an inter partes review (IPR) proceeding filed by Acrux against U.S. Patent no. 7,214,506.Patent relates to methods of using various antifungal compounds, including efinaconazole, for treatment of onychomycosis.U.S. Patent No. 7,214,506 is owned by Kaken Pharmaceutical Co Ltd. and licensed to Valeant Pharmaceuticals International Inc.  Full Article

Kaken Pharmaceutical gets domestic manufacture and marketing approval for periodontium regeneration medicine
Wednesday, 28 Sep 2016 03:26am EDT 

Kaken Pharmaceutical Co Ltd <4521.T>:Says it received domestic manufacture and marketing approval for a periodontium regeneration medicine.  Full Article

Kaken Pharmaceutical to co-promote allergic medicine with Kyorin Holdings unit
Monday, 11 Jul 2016 02:00am EDT 

Kaken Pharmaceutical Co Ltd <4521.T>:Says the company entered into basic agreement with Kyorin Holdings Inc <4569.T>'s unit on co-promotion of an allergic medicine, whose exclusive sales right is owned by the Kyorin Holdings's unit.  Full Article

Kaken Pharmaceutical appoints ARK MEIJI AUDIT & Co. as auditor
Thursday, 30 Jun 2016 10:09pm EDT 

Kaken Pharmaceutical Co Ltd <4521.T>:Says it appointed ARK MEIJI AUDIT & Co. as auditor, effective July 1.  Full Article

Kaken Pharmaceutical signs agreement with Dong-A ST for Clenafin/Jublia in Korea
Monday, 30 May 2016 11:03pm EDT 

Kaken Pharmaceutical Co Ltd <4521.T> : Says Kaken Pharmaceutical <4521.T> and A Korea-based firm Dong-A ST Co Ltd <170900.KS> concluded an exclusive distribution agreement for the topical formulation for Onychomycosis “Clenafin / Jublia” in Korea .Says according to the agreement, Kaken hereby grant to Dong-A the exclusive right for development and sales of the Product in Korea.  Full Article

KAKEN PHARMACEUTICAL signs exclusive licensing contract
Tuesday, 26 Apr 2016 03:30am EDT 

KAKEN PHARMACEUTICAL CO LTD:Signed a licensing contract with MediWound Ltd., and MediWound Ltd. to granted the company exclusive development and sale rights in Japan for burn eschar remover (NexoBrid®).  Full Article

KAKEN PHARMACEUTICAL to merge with subsidiary
Tuesday, 27 Oct 2015 03:00am EDT 

KAKEN PHARMACEUTICAL CO LTD:To merge with its Tokyo-based wholly owned subsidiary on March 31, 2016.Says the subsidiary to be dissolved after the transaction.  Full Article

KAKEN PHARMACEUTICAL raises consolidated mid-year and full-year outlook and dividend forecast for FY 2016
Tuesday, 27 Oct 2015 03:00am EDT 

KAKEN PHARMACEUTICAL CO LTD:Says the company increased the consolidated mid-year outlook for revenue to 55,000 mln yen from 48,800 mln yen, for the fiscal year ending March 2016.Operating profit forecast increased to 18,400 mln yen from 10,500 mln yen.Ordinary profit forecast increased to 18,600 mln yen from 10,600 mln yen.Net profit forecast increased to 12,500 mln yen from 7,100 mln yen.Earnings per share increased to 301.86 yen from 171.46 yen.Says the company increased the consolidated full-year outlook for revenue to 107,900 mln yen from 98,500 mln yen, for the fiscal year ending March 2016.Operating profit forecast increased to 32,200 mln yen from 21,000 mln yen.Ordinary profit forecast increased to 32,400 mln yen from mln yen.Net profit forecast increased to 19,200 mln yen from 14,000 mln yen.Earnings per share increased to 463.66 yen from 338.09 yen.Says it raised the year-end dividend forecast to 78 yen per share from 68 yen per share for the fiscal year ending March 2016.  Full Article

BRIEF- Kaken Pharmaceutical to begin sale of Jublia in Korea

* Says its partner company Dong-A ST Co., Ltd. will begin the sale of Jublia, a topical formulation drug for Onychomycosis, in Korea, from June 1